Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | - |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| - | - | - |
ClearBridge Large Cap Growth Strategy significantly underperformed the Russell 1000 Growth Index in 2025, trailing by approximately 900 basis points as the benchmark surged 18.6%. The primary headwind was underweights to mega cap AI beneficiaries like Alphabet and Broadcom, along with poor stock selection in healthcare including exits from UnitedHealth Group and Eli Lilly. While the managers correctly positioned in Nvidia since 2018, they underestimated the magnitude of AI spending growth and the market's momentum-driven rally. Post-Liberation Day, they actively repositioned by purchasing Broadcom, Marvell Technology, Datadog and Oracle while exiting lower-conviction names. The managers acknowledge the need to be more proactive when secular themes emerge but believe the current sentiment-driven environment is unsustainable. They expect resurgent growth in the economy ex-tech from fiscal stimulus and easing monetary policy to support broader market participation. The portfolio is being positioned for this transition while maintaining selective exposure to high-quality AI beneficiaries and exploring opportunities in healthcare and short-cycle industrials.
Despite meaningful underperformance due to underweights in mega cap AI beneficiaries, the managers believe the current momentum-driven growth market is unsustainable and are positioning for broader market participation while selectively upgrading AI exposure through higher-quality names.
The managers expect continued AI development with potential for broadening market participation as growth in the economy ex-tech accelerates from fiscal stimulus and easing monetary policy. They anticipate ongoing volatility in AI-related names as monetization models become clearer and are positioning for opportunities in healthcare and short-cycle industrials.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 7 2026 | 2025 Q4 | ACN, ADBE, ANET, AVGO, CMG, DDOG, EQIX, ETN, GOOGL, ISRG, LLY, MRVL, NVDA, ORCL, PLTR, SBUX, TMO, UNH, VRTX, WDAY | AI, growth, healthcare, large cap, momentum, semiconductors, technology, underperformance | - | AI spending exceeded expectations with hyperscalers accelerating capex, emergence of OpenAI and Anthropic as major spending sources, and Alphabet selling custom AI chips to competitors.… |
| Oct 1 2025 | 2025 Q3 | ACN, AVGO, CMG, DDOG, UNH, UNP, WDAY | AI, Broadcom, Datadog, Oracle, technology |
ORCL US DDOG US VRTX US |
The letter discusses dispersion between AI winners and losers, emphasizing disciplined exposure rather than momentum chasing. Infrastructure software and select cyclicals are positioned to benefit… |
| Jul 29 2025 | 2025 Q2 | AIR FP, ICLR, LIN, MRVL, NOW, TSM | AI, Balance Sheets, earnings durability, secular growth, valuation |
TSM MRVL NOW AIR FP LIN ICLR |
The letter emphasizes sustained earnings growth driven by secular themes such as AI adoption, cloud computing and digital transformation. Management highlights high-quality large-cap companies with… |
| Apr 8 2025 | 2025 Q1 | ALC SW, SNPS | - | - | - |
| Jan 7 2025 | 2024 Q4 | ARNB, AVGO, ICON, NEE, NVO, TSLA | - | - | - |
| Sep 30 2024 | 2024 Q3 | ACN, APTV, CMG, EL, NVDA, SBUX, TEAM | - | - | - |
| Jun 30 2024 | 2024 Q2 | PANW, PYPL | - | - | - |
| Apr 20 2024 | 2024 Q1 | PYPL, UNH | - | - | - |
| Mar 1 2024 | 2023 Q4 | AMZN, DXCM, EL, ICE, MFT, NVDA, SPLK, U | - | - | - |
| Nov 10 2023 | 2023 Q3 | EL, LLY, NKE, NVDA, SE, TGT, UNH, UNP, V | - | - | - |
| Jun 30 2023 | 2023 Q2 | ADBE, NVDA | - | - | - |
| Mar 31 2023 | 2023 Q1 | LLY, MSFT, NEE, NVDA | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
CloudAmazon's positioning to benefit from both infrastructure and application layers of AI is highlighted. The company's logistical prowess represents one of the foremost moats in business and will be enhanced with AI through better orchestration of logistics assets and buildout of more sophisticated robotics. |
Infrastructure Logistics Automation Efficiency Coordination | |
SemiconductorsRGA initiated a position in Lattice Semiconductor, viewing it as an under-appreciated AI winner with immediate gains and longer-term optionality. Lattice's focus on efficiency and advantages in low-power, small footprint FPGAs position it favorably for AI servers, particularly as the only Post-Quantum Cryptography secure chips on the market. |
FPGAs Security Efficiency AI Infrastructure Programmable | |
TechnologyThe fund added three technology companies that have each halved over 2025 and hopes to add more. Many tech stocks had become expensive but recent falls present opportunities, though most still aren't cheap enough including Xero. |
Software Valuation Opportunity Selloff | |
| 2025 Q3 |
AIAI has been integrated into RGA's research process through tools like NotebookLM, Gems in Gemini, and Claude Code. The firm views AI as a force multiplier for human judgment rather than a replacement, emphasizing the Kasparov Law principle. They believe the market narrative around AI displacement is swinging to unhelpful extremes, creating investment opportunities. |
Machine Learning Automation Software Productivity Innovation |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech | |
Technology |
||
| 2025 Q2 |
Growth |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | ICLR | ICON plc | Health Care | Life Sciences Tools & Services | Bear | NASDAQ | Funding, Normalization, Outsourcing, Pipelines, visibility | Login |
| Oct 1, 2025 | Fund Letters | Peter Bourbeau | ORCL US | Oracle Corp. | Information Technology | Systems Software | Bull | NYSE | AI, cloud, FCF, growth, infrastructure, Margins, Software, valuation | Login |
| Oct 1, 2025 | Fund Letters | Peter Bourbeau | DDOG US | Datadog, Inc. | Information Technology | Application Software | Bull | NASDAQ | AI, cloud, growth, innovation, Margins, observability, SaaS | Login |
| Oct 1, 2025 | Fund Letters | Peter Bourbeau | VRTX US | Vertex Pharmaceuticals Inc. | Health Care | Biotechnology | Bull | NASDAQ | Biotech, cash, Cystic fibrosis, growth, Pain, pipeline, R&D, valuation | Login |
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | TSM | Taiwan Semiconductor Manufacturing Company Limited | Information Technology | Semiconductors | Bear | NYSE | CapEx, Concentration, Geopolitics, Risk, semiconductors | Login |
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | MRVL | Marvell Technology, Inc. | Information Technology | Semiconductors | Bull | NASDAQ | AI, Interconnect, Networking, semiconductors, valuation | Login |
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | NOW | ServiceNow, Inc. | Information Technology | Systems Software | Bull | NYSE | AI, Automation, Margins, SaaS, Workflows | Login |
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | AIR FP | Airbus SE | Industrials | Aerospace & Defense | Bull | Euronext Stock Exchange | Aerospace, backlog, cashflow, Defense, Travel | Login |
| Jul 29, 2025 | Fund Letters | Peter Bourbeau | LIN | Linde plc | Materials | Industrial Gases | Bull | NYSE | cashflow, Gases, Industrial, Pricing, Space | Login |
| TICKER | COMMENTARY |
|---|---|
| ACN | Accenture is the world's leading IT consultant, with advantages stemming from their depth and breadth across products, geographies, and industries. Over the last four years, Accenture's valuation has roughly halved. They've faced headwinds in IT spending and suffered from the perception that they are an AI loser. We believe that AI will cause deflationary pressure in parts of their business, but that it will be more than offset by the work required for enterprises to adopt AI. This is recently evidenced by partnerships with OpenAI and Anthropic. |
| ADBE | By looking at their Rnancials, FactSet, PayPal, Adobe, and Salesforce seem to be doing Rne. The market, however, is reading subdued revenue growth as a sign of increased competition on their core oSerings. These companies' outlooks look more di'cult than their past. |
| ANET | ASML, TSMC, and Arista Networks are key players in the AI build out supply chain. |
| AVGO | The primary contributors to its performance were our exposures to Broadcom |
| CMG | The top-five detractors from returns were Fiserv, Chipotle, Constellation Software, Roper, and Floor & Décor. In the quarter, we exited Fiserv, Chipotle, and monday.com. |
| EQIX | Data center operator Equinix should benefit from the growing importance of sharing data across clouds, but the returns on a large capital spending project will delay revenue growth acceleration until 2027. We view the company as a later stage AI beneficiary, especially if all the current spending begins to produce a positive return on investment. |
| ETN | Eaton's shares pulled back in August following strong performance through July. Like many companies in the industrials complex, Eaton's results did not exceed very high investor expectations. Moving into 2026, we anticipate accelerated growth for the company that is tied to strong trends in data center, aerospace, and defense markets. |
| GOOGL | In the third quarter, Google, Kairos Power, and the Tennessee Valley Authority announced a major collaboration centered on a novel power purchase agreement. Google followed this announcement with another significant step forward. On October 27, Google and NextEra Energy announced plans to restart the Duane Arnold Energy Center. |
| ISRG | ISRG shares appreciated in the fourth quarter after the company delivered strong Q3 results highlighting continued procedure growth and accelerating system placements. Procedure volumes rose in the mid-teens globally, with notable strength in general surgery and urology, while recurring instrument and accessory revenue grew faster than expectations. Management also reported that the early rollout of its next-generation robotic platform was tracking ahead of schedule, with utilization metrics trending positively across beta sites. |
| LLY | Eli Lilly shares were a top performer in 4Q25 after delivering strong Q3 2025 earnings in October. Revenue rose 54% year-over-year to $17.6 billion, and adjusted EPS of $7.02 beat consensus of $6.02. Growth was driven by its GLP-1 franchises, Mounjaro and Zepbound, where sales more than doubled year-over-year, alongside strength in other therapeutic areas. Management raised full-year guidance for both revenue and earnings, reinforcing investor confidence in the company's growth outlook. |
| MRVL | We also initiated a position in Marvell Technology which is a fabless semiconductor company that supplies technology necessary to move, store, process and secure data across various end-markets such as data centers, enterprise networks and telecommunications infrastructure. We believe the risk/reward looks compelling and we elected to start a position on the stock's recent pullback. |
| NVDA | AI bellwether NVIDIA's very strong set of earnings in late November helped the AI theme re-assert its dominance when investors breathed a sigh of relief following the results. |
| ORCL | Investor enthusiasm for Oracle's stock in calendar year 2025 was initially driven by several multi-billion-dollar contracts it signed with leading AI companies, including OpenAI and Meta. However, in Q4 sentiment for ORCL's growth prospects shifted to skepticism, as investors began to scrutinize the return profile of the substantial capital investments required to support the approximately $500 billion of contracts signed by Oracle. Given the widening range of potential outcomes associated with Oracle's elevated capital needs, we reduced our position in ORCL during Q4. |
| PLTR | The top three contributors to this outperformance came from Palantir Technologies (US Defense) |
| SBUX | Starbucks was sold during the quarter as it was not tracking to plan. |
| TMO | Thermo Fisher Scientific was a strong contributor with 8.69% ending weight and 1.47% contribution. |
| UNH | We also added back a full position in UnitedHealth |
| VRTX | Top gainers in the Fund this quarter included Vertex Pharmaceuticals (+16%) |
| WDAY | Finally, we have exited our relatively small position in Workday. The company's growth has decelerated the past few quarters and the Financials segment of the business (~25% of sales) is growing slower than we believe it should be. This is a company we may revisit at a later date but, for now, feel that we have better opportunities in other areas of the portfolio. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||